Partnerships Through Creativity
The ever increasing opportunities flowing from biotechnology and pharmaceutical development provide Chugai Pharma USA with the ability to create new value for both itself and its strategic partners. That's why Chugai Pharma USA continues to look at external opportunities to complement its internal development strengths.
Chugai has a long history as a successful partner. From our very successful relationship with Hofmann LaRoche and other major pharmaceutical companies, we see value in building successful partnerships. We believe in 'win-win' arrangements with benefits accruing to both parties in an equitable manner. Once a licensed-in product enters Chugai's pipeline, we bring the breadth of Chugai's global resources, talent and experience to getting the product to the market and them optimizing its success in markets worldwide.
Currently, the focus of Chugai Pharma is to both grow in its US business and to supplement our existing development opportunities with complementary external arrangements. This includes not only early-stage research collaborations leading to a compound for development, but also innovative arrangements involving products that are either established or in later stages of development.
Chugai is an extremely stable company, intensely focused on developing and delivering breakthrough products. We strongly believe in the value of 'win-win' collaborations with benefits accruing to both parties in an equitable manner. We are able to provide our partners with an expanded review and decision process. We understand the value of a timely review to our partners.
We believe we have the necessary qualities for successful partnering - creativity, commitment, flexibility and experience - supported by a strong technological, business and financial infrastructure. We move quickly and aim for win-win opportunities.
Product candidates coming from collaborations are fully integrated into the Chugai drug development process, with the same level of rigor and resources devoted to licensed products as internally discovered product candidates.
